

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 3 | 1.6 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 1 | 0.8 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 2 | 5.9 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 6 | 2.2 | 272.9 | (99.6-594.0) | Female | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 8 | 6.5 | 122.9 | (52.9-242.1) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | Female | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Female | 2 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 34 | 22.5 | 151.1 | (104.6-211.1) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 13 | 19.5 | 66.7 | (35.5-114.1) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 6 | 3.0 | 202.6 | (74.0-440.9) | <u>All Sites / Types</u> | | | | |
| Female | 1 | 2.6 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 5.6 | nc | (nc-nc) | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) | Female | 4 | 3.3 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 1.4 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 5 | 3.5 | 143.7 | (46.3-335.3) |
| Female | 24 | 22.0 | 109.3 | (70.0-162.6) | Female | 3 | 2.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.1 | nc | (nc-nc) | Male | 1 | 2.6 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 8 | 8.0 | 99.6 | (42.9-196.3) | Female | 4 | 2.1 | nc | (nc-nc) |
| Female | 10 | 6.5 | 155.0 | (74.2-285.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 1.6 | nc | (nc-nc) | Male | 17 | 22.3 | 76.3 | (44.4-122.2) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 4 | 3.1 | nc | (nc-nc) | Female | 2 | 4.7 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 64 | 80.8 | 79.2 | (61.0-101.1) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 79 | 72.1 | 109.6 | (86.7-136.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 2.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 1 | 1.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 2 | 1.6 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 8 | 10.3 | 77.4 | (33.3-152.5) | <u>All Sites / Types</u> | | | | |
| Female | 10 | 8.9 | 111.9 | (53.6-205.7) | <u>All Sites / Types</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 50 | 43.7 | 114.4 | (84.9-150.9) | Male | 21 | 27.3 | 77.0 | (47.6-117.7) |
| Female | 26 | 17.6 | 147.8 | (96.5-216.6) | Female | 21 | 24.1 | 87.1 | (53.9-133.2) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 8.4 | 71.2 | (26.0-155.0) | Male | 3 | 6.8 | nc | (nc-nc) |
| Female | 3 | 7.5 | nc | (nc-nc) | Female | 5 | 5.6 | 89.4 | (28.8-208.7) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Male | 30 | 23.5 | 127.8 | (86.2-182.5) |
| Female | 163 | 166.6 | 97.8 | (83.4-114.1) | Female | 22 | 22.7 | 96.8 | (60.6-146.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 8 | 7.1 | 113.0 | (48.7-222.8) | Male | 16 | 16.0 | 99.8 | (57.0-162.0) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 60 | 57.6 | 104.1 | (79.5-134.1) | Female | 17 | 17.1 | 99.3 | (57.8-159.1) |
| Female | 67 | 61.6 | 108.8 | (84.3-138.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 12 | 13.2 | 90.8 | (46.9-158.6) |
| Male | 11 | 11.1 | 99.0 | (49.3-177.1) | Female | 23 | 15.3 | 150.8 | (95.6-226.3) |
| Female | 5 | 3.3 | 149.5 | (48.2-348.9) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 134 | 158.5 | 84.5 | (70.8-100.1) |
| Male | 3 | 3.9 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 3 | 3.5 | nc | (nc-nc) | Male | 17 | 10.2 | 167.4 | (97.4-268.0) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 10 | 6.9 | 146.0 | (69.9-268.5) |
| Male | 15 | 20.9 | 71.7 | (40.1-118.2) | <u>Testis</u> | | | | |
| Female | 12 | 13.9 | 86.6 | (44.7-151.3) | Male | 5 | 6.7 | 75.1 | (24.2-175.3) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 8 | 6.6 | 120.8 | (52.0-238.1) | Male | 11 | 7.6 | 145.5 | (72.5-260.4) |
| Female | 3 | 2.0 | nc | (nc-nc) | Female | 30 | 26.7 | 112.4 | (75.8-160.5) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 25 | 15.0 | 166.7 | (107.9-246.1) | Female | 30 | 36.9 | 81.3 | (54.9-116.1) |
| Female | 11 | 12.5 | 88.2 | (44.0-157.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 595 | 571.9 | 104.0 | (95.8-112.7) |
| Male | 6 | 10.4 | 57.9 | (21.2-126.1) | Female | 628 | 595.8 | 105.4 | (97.3-114.0) |
| Female | 4 | 4.1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 104 | 79.1 | 131.4 | (107.4-159.2) | | | | | |
| Female | 96 | 84.2 | 114.1 | (92.4-139.3) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 13 | 8.7 | 148.9 | (79.2-254.7) | Male | 5 | 5.9 | 85.3 | (27.5-199.1) |
| Female | 6 | 3.0 | 198.7 | (72.6-432.5) | Female | 4 | 4.5 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 1.8 | nc | (nc-nc) | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) | Female | 0 | 1.0 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 31 | 32.4 | 95.7 | (65.0-135.8) | Female | 6 | 4.0 | 149.6 | (54.6-325.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 3 | 1.4 | nc | (nc-nc) | Male | 3 | 3.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 8 | 12.0 | 66.8 | (28.7-131.6) | Female | 0 | 3.2 | nc | (nc-nc) |
| Female | 12 | 10.3 | 116.1 | (59.9-202.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 2.8 | nc | (nc-nc) |
| Male | 4 | 2.4 | nc | (nc-nc) | Female | 2 | 2.6 | nc | (nc-nc) |
| Female | 2 | 0.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 28 | 35.2 | 79.6 | (52.9-115.0) |
| Male | 0 | 0.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.6 | nc | (nc-nc) | Male | 0 | 2.1 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 3 | 1.1 | nc | (nc-nc) |
| Male | 7 | 4.6 | 152.9 | (61.2-315.0) | <u>Testis</u> | | | | |
| Female | 2 | 2.6 | nc | (nc-nc) | Male | 2 | 1.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 6 | 1.5 | 409.5 | (149.5-891.4) | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 3 | 5.2 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 3.1 | nc | (nc-nc) | Female | 9 | 7.4 | 121.6 | (55.5-230.8) |
| Female | 0 | 2.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 121 | 121.5 | 99.6 | (82.7-119.0) |
| Male | 1 | 2.3 | nc | (nc-nc) | Female | 128 | 109.5 | 116.9 | (97.5-139.0) |
| Female | 1 | 0.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 19 | 16.3 | 116.8 | (70.3-182.4) | | | | | |
| Female | 31 | 15.2 | 204.2 | (138.7-289.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 1.5 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 1 | 0.5 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 3.5 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 2.0 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 0.5 | nc | (nc-nc) |
| Male | 0 | 0.4 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 2 | 5.6 | nc | (nc-nc) |
| Male | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.1 | nc | (nc-nc) |
| Male | 0 | 0.7 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 6 | 19.5 | 30.8 | (11.3-67.1) |
| Male | 0 | 0.4 | nc | (nc-nc) | Female | 6 | 11.8 | 51.0 | (18.6-111.0) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 2 | 2.8 | nc | (nc-nc) | | | | | |
| Female | 1 | 1.7 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 30 | 24.0 | 125.1 | (84.4-178.7) | Male | 21 | 14.8 | 142.2 | (88.0-217.4) |
| Female | 10 | 8.6 | 116.9 | (56.0-215.1) | Female | 16 | 11.7 | 136.8 | (78.1-222.1) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 9 | 4.6 | 196.2 | (89.5-372.4) | Male | 9 | 3.7 | 243.4 | (111.1-462.1) |
| Female | 4 | 3.7 | nc | (nc-nc) | Female | 2 | 2.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 16 | 12.8 | 124.8 | (71.3-202.6) |
| Female | 98 | 83.9 | 116.8 | (94.8-142.3) | Female | 12 | 11.0 | 108.6 | (56.1-189.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 3 | 3.5 | nc | (nc-nc) | Male | 8 | 8.8 | 90.8 | (39.1-178.9) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 38 | 31.6 | 120.3 | (85.1-165.1) | Female | 12 | 8.4 | 142.2 | (73.4-248.5) |
| Female | 21 | 29.9 | 70.2 | (43.4-107.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 9 | 7.3 | 123.8 | (56.5-235.0) |
| Male | 7 | 6.1 | 114.6 | (45.9-236.1) | Female | 6 | 7.4 | 80.9 | (29.5-176.0) |
| Female | 1 | 1.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 129 | 85.6 | 150.8 | (125.9-179.1) |
| Male | 3 | 1.9 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.5 | nc | (nc-nc) | Male | 5 | 5.6 | 89.9 | (29.0-209.9) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 3.3 | nc | (nc-nc) |
| Male | 16 | 11.5 | 139.3 | (79.6-226.2) | <u>Testis</u> | | | | |
| Female | 10 | 6.8 | 146.1 | (70.0-268.8) | Male | 5 | 3.0 | 168.7 | (54.4-393.8) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 6 | 3.6 | 166.2 | (60.7-361.7) | Male | 2 | 4.0 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) | Female | 5 | 13.0 | 38.5 | (12.4-89.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 13 | 8.2 | 159.5 | (84.8-272.7) | Female | 19 | 18.4 | 103.4 | (62.2-161.4) |
| Female | 10 | 6.1 | 164.8 | (78.9-303.1) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 397 | 310.7 | 127.8 | (115.5-141.0) |
| Male | 5 | 5.7 | 87.7 | (28.3-204.6) | Female | 305 | 293.5 | 103.9 | (92.6-116.3) |
| Female | 2 | 2.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 47 | 43.3 | 108.5 | (79.7-144.2) | | | | | |
| Female | 34 | 41.2 | 82.6 | (57.2-115.4) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 47 | 37.4 | 125.7 | (92.3-167.1) | Male | 13 | 22.2 | 58.5 | (31.1-100.0) |
| Female | 10 | 13.6 | 73.6 | (35.3-135.4) | Female | 11 | 17.2 | 64.1 | (32.0-114.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 6.5 | 77.1 | (24.8-179.9) | Male | 6 | 5.7 | 104.9 | (38.3-228.2) |
| Female | 8 | 5.3 | 149.9 | (64.5-295.4) | Female | 5 | 4.3 | 116.0 | (37.4-270.6) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 1.1 | nc | (nc-nc) | Male | 24 | 19.2 | 125.3 | (80.3-186.5) |
| Female | 140 | 126.6 | 110.6 | (93.0-130.5) | Female | 23 | 17.2 | 134.0 | (84.9-201.0) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 4.9 | nc | (nc-nc) | Male | 14 | 13.4 | 104.7 | (57.2-175.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 52 | 48.7 | 106.7 | (79.7-139.9) | Female | 11 | 12.9 | 85.1 | (42.4-152.3) |
| Female | 47 | 46.6 | 100.9 | (74.1-134.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 11 | 11.3 | 97.1 | (48.4-173.7) |
| Male | 8 | 9.5 | 84.1 | (36.2-165.8) | Female | 12 | 11.7 | 102.7 | (53.0-179.4) |
| Female | 1 | 2.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 128 | 137.5 | 93.1 | (77.7-110.7) |
| Male | 0 | 2.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 2.0 | nc | (nc-nc) | Male | 10 | 8.6 | 116.6 | (55.8-214.4) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 5 | 5.1 | 97.3 | (31.4-227.1) |
| Male | 22 | 17.4 | 126.2 | (79.0-191.0) | <u>Testis</u> | | | | |
| Female | 12 | 10.6 | 113.0 | (58.3-197.4) | Male | 7 | 3.9 | 180.6 | (72.3-372.0) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 6 | 5.7 | 105.6 | (38.6-229.8) | Male | 7 | 5.7 | 122.4 | (49.0-252.3) |
| Female | 1 | 1.6 | nc | (nc-nc) | Female | 20 | 18.0 | 111.1 | (67.8-171.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 12.1 | 66.0 | (28.4-130.1) | Female | 30 | 28.8 | 104.2 | (70.3-148.7) |
| Female | 10 | 9.1 | 110.3 | (52.8-202.9) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 498 | 481.6 | 103.4 | (94.5-112.9) |
| Male | 12 | 8.7 | 138.3 | (71.4-241.7) | Female | 464 | 449.7 | 103.2 | (94.0-113.0) |
| Female | 1 | 3.1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 77 | 68.0 | 113.3 | (89.4-141.6) | | | | | |
| Female | 74 | 66.1 | 112.0 | (87.9-140.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 3 | 2.6 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 4 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 4 | 1.5 | nc | (nc-nc) | Male | 14 | 11.2 | 125.2 | (68.4-210.0) |
| Female | 1 | 1.1 | nc | (nc-nc) | Female | 7 | 8.7 | 80.6 | (32.3-166.0) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 27 | 22.9 | 117.9 | (77.7-171.5) | Male | 31 | 14.3 | 217.1 | (147.5-308.2) |
| Female | 3 | 8.3 | nc | (nc-nc) | Female | 20 | 11.1 | 180.6 | (110.3-279.0) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 4.3 | nc | (nc-nc) | Male | 4 | 3.6 | nc | (nc-nc) |
| Female | 4 | 3.5 | nc | (nc-nc) | Female | 5 | 2.6 | 189.2 | (61.0-441.5) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 14 | 12.1 | 115.6 | (63.2-194.0) |
| Female | 88 | 82.3 | 106.9 | (85.8-131.7) | Female | 9 | 10.7 | 84.4 | (38.5-160.2) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 3.2 | nc | (nc-nc) | Male | 15 | 8.9 | 169.1 | (94.6-279.0) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 30 | 30.5 | 98.5 | (66.4-140.6) | Female | 4 | 8.3 | nc | (nc-nc) |
| Female | 30 | 28.6 | 105.1 | (70.9-150.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 7.1 | nc | (nc-nc) |
| Male | 6 | 6.1 | 98.3 | (35.9-213.9) | Female | 6 | 7.1 | 84.2 | (30.8-183.3) |
| Female | 1 | 1.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 103 | 89.9 | 114.6 | (93.5-139.0) |
| Male | 2 | 1.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 5 | 1.3 | 391.0 | (126.0-912.4) | Male | 6 | 5.3 | 113.4 | (41.4-246.9) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 4 | 3.1 | nc | (nc-nc) |
| Male | 8 | 11.4 | 70.3 | (30.3-138.6) | <u>Testis</u> | | | | |
| Female | 4 | 6.7 | nc | (nc-nc) | Male | 4 | 2.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 3.7 | nc | (nc-nc) | Male | 6 | 3.8 | 155.9 | (56.9-339.4) |
| Female | 0 | 1.0 | nc | (nc-nc) | Female | 11 | 12.1 | 91.1 | (45.4-163.0) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 9 | 7.6 | 118.1 | (53.9-224.2) | Female | 18 | 18.7 | 96.5 | (57.2-152.5) |
| Female | 11 | 5.7 | 191.8 | (95.6-343.1) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 354 | 307.1 | 115.3 | (103.6-127.9) |
| Male | 5 | 5.7 | 88.0 | (28.3-205.3) | Female | 296 | 285.3 | 103.8 | (92.3-116.3) |
| Female | 1 | 1.9 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 41 | 42.7 | 95.9 | (68.8-130.1) | | | | | |
| Female | 41 | 41.0 | 100.0 | (71.7-135.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 23 | 16.0 | 144.0 | (91.2-216.1) | Male | 13 | 10.2 | 127.1 | (67.6-217.4) |
| Female | 5 | 5.2 | 95.7 | (30.8-223.3) | Female | 4 | 7.6 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 3.1 | nc | (nc-nc) | Male | 2 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.4 | nc | (nc-nc) | Female | 1 | 1.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 10 | 8.7 | 114.8 | (55.0-211.2) |
| Female | 70 | 55.1 | 127.0 | (99.0-160.5) | Female | 9 | 6.9 | 130.7 | (59.6-248.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 2.3 | nc | (nc-nc) | Male | 7 | 6.3 | 110.3 | (44.2-227.2) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 18 | 21.5 | 83.7 | (49.6-132.4) | Female | 3 | 5.4 | nc | (nc-nc) |
| Female | 21 | 18.1 | 116.3 | (72.0-177.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 8 | 4.9 | 161.7 | (69.6-318.6) |
| Male | 4 | 4.3 | nc | (nc-nc) | Female | 6 | 4.5 | 133.9 | (48.9-291.4) |
| Female | 1 | 1.0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 59 | 61.7 | 95.7 | (72.8-123.4) |
| Male | 2 | 1.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 1.0 | nc | (nc-nc) | Male | 3 | 3.7 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 2.0 | nc | (nc-nc) |
| Male | 8 | 8.0 | 99.5 | (42.8-196.0) | <u>Testis</u> | | | | |
| Female | 5 | 4.4 | 114.2 | (36.8-266.6) | Male | 0 | 2.0 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 2.6 | nc | (nc-nc) | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 11 | 8.8 | 124.9 | (62.2-223.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 5.4 | 147.5 | (63.5-290.6) | Female | 13 | 12.2 | 106.5 | (56.7-182.2) |
| Female | 5 | 3.7 | 134.2 | (43.2-313.1) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 209 | 215.3 | 97.1 | (84.4-111.2) |
| Male | 0 | 4.1 | nc | (nc-nc) | Female | 209 | 187.1 | 111.7 | (97.1-127.9) |
| Female | 1 | 1.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 26 | 29.5 | 88.0 | (57.5-129.0) | | | | | |
| Female | 30 | 25.9 | 115.7 | (78.0-165.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 16 | 17.3 | 92.4 | (52.8-150.0) | Male | 13 | 11.7 | 110.8 | (58.9-189.4) |
| Female | 2 | 5.9 | nc | (nc-nc) | Female | 19 | 9.2 | 206.2 | (124.1-322.0) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 3.8 | nc | (nc-nc) | Male | 2 | 2.8 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) | Female | 4 | 1.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 3 | 0.5 | nc | (nc-nc) | Male | 17 | 9.9 | 170.9 | (99.5-273.7) |
| Female | 80 | 67.5 | 118.5 | (93.9-147.4) | Female | 7 | 8.0 | 87.9 | (35.2-181.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 3 | 2.9 | nc | (nc-nc) | Male | 6 | 7.5 | 79.8 | (29.1-173.7) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 15 | 24.1 | 62.3 | (34.9-102.8) | Female | 6 | 6.5 | 91.8 | (33.5-199.7) |
| Female | 24 | 20.9 | 115.0 | (73.7-171.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 8 | 5.5 | 146.4 | (63.1-288.6) |
| Male | 7 | 4.8 | 145.1 | (58.1-299.0) | Female | 11 | 5.1 | 215.1 | (107.2-385.0) |
| Female | 2 | 1.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 66 | 68.9 | 95.8 | (74.1-121.9) |
| Male | 2 | 1.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 1.1 | nc | (nc-nc) | Male | 4 | 4.1 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 2.3 | nc | (nc-nc) |
| Male | 3 | 9.3 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 10 | 5.1 | 194.2 | (93.0-357.2) | Male | 2 | 2.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 2.9 | 173.0 | (55.8-403.8) | Male | 6 | 3.4 | 174.4 | (63.7-379.6) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 23 | 10.9 | 211.2 | (133.9-316.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 6 | 6.2 | 96.5 | (35.2-210.0) | Female | 17 | 14.7 | 115.3 | (67.1-184.6) |
| Female | 6 | 4.4 | 135.5 | (49.5-294.9) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 237 | 241.5 | 98.1 | (86.0-111.5) |
| Male | 4 | 4.8 | nc | (nc-nc) | Female | 271 | 222.0 | 122.1 | (108.0-137.5) |
| Female | 1 | 1.4 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 28 | 32.2 | 86.9 | (57.7-125.5) | | | | | |
| Female | 31 | 29.3 | 105.7 | (71.8-150.0) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 4 | 4.6 | nc | (nc-nc) | Male | 3 | 2.8 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) | Female | 2 | 2.0 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 0.8 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 18 | 14.9 | 120.8 | (71.6-190.9) | Female | 1 | 1.9 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 0.6 | nc | (nc-nc) | Male | 3 | 1.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 6.1 | nc | (nc-nc) | Female | 4 | 1.5 | nc | (nc-nc) |
| Female | 6 | 5.1 | 118.7 | (43.3-258.4) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 1 | 1.2 | nc | (nc-nc) | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 1.3 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 14 | 17.5 | 80.0 | (43.7-134.3) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 2 | 2.2 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) | Female | 1 | 0.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 2 | 0.7 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 2 | 1.5 | nc | (nc-nc) | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) | Female | 3 | 2.2 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 1.1 | nc | (nc-nc) | Female | 1 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 7 | 8.5 | 82.8 | (33.2-170.5) | Male | 52 | 60.5 | 86.0 | (64.2-112.7) |
| Female | 5 | 7.5 | 66.6 | (21.5-155.4) | Female | 50 | 51.5 | 97.0 | (72.0-127.9) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 3.0 | nc | (nc-nc) | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) | Female | 1 | 1.4 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 1 | 0.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 9 | 10.6 | 84.6 | (38.6-160.6) | Female | 1 | 1.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.4 | nc | (nc-nc) | Male | 4 | 1.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 3.9 | nc | (nc-nc) | Female | 0 | 1.1 | nc | (nc-nc) |
| Female | 4 | 4.5 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 0.9 | nc | (nc-nc) |
| Male | 0 | 0.8 | nc | (nc-nc) | Female | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 6 | 11.1 | 54.2 | (19.8-118.0) |
| Male | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 0.5 | nc | (nc-nc) |
| Male | 0 | 1.4 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.9 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) | Female | 1 | 1.4 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.0 | nc | (nc-nc) | Female | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 27 | 38.7 | 69.7 | (45.9-101.4) |
| Male | 0 | 0.7 | nc | (nc-nc) | Female | 31 | 39.2 | 79.1 | (53.7-112.2) |
| Female | 0 | 0.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 4 | 5.4 | nc | (nc-nc) | | | | | |
| Female | 3 | 5.7 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 3 | 4.7 | nc | (nc-nc) | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) | Female | 2 | 2.3 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 1.0 | nc | (nc-nc) | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) | Female | 1 | 0.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 5 | 2.6 | 190.3 | (61.3-444.1) |
| Female | 18 | 17.1 | 105.3 | (62.4-166.5) | Female | 1 | 1.9 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Male | 4 | 2.0 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 7 | 6.5 | 107.3 | (43.0-221.0) | Female | 0 | 1.6 | nc | (nc-nc) |
| Female | 6 | 5.0 | 119.4 | (43.6-259.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 2 | 1.3 | nc | (nc-nc) | Male | 19 | 19.2 | 98.8 | (59.5-154.3) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 2.5 | nc | (nc-nc) | Female | 5 | 3.8 | 130.0 | (41.9-303.3) |
| Female | 0 | 1.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 64 | 65.6 | 97.5 | (75.1-124.5) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 56 | 55.2 | 101.5 | (76.7-131.8) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 1.6 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 1.1 | nc | (nc-nc) | Male | 64 | 65.6 | 97.5 | (75.1-124.5) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1.3 | nc | (nc-nc) | Female | 56 | 55.2 | 101.5 | (76.7-131.8) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 2 | 8.9 | nc | (nc-nc) | Male | 64 | 65.6 | 97.5 | (75.1-124.5) |
| Female | 8 | 7.3 | 109.8 | (47.3-216.4) | Female | 56 | 55.2 | 101.5 | (76.7-131.8) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 4 | 6.4 | nc | (nc-nc) | Male | 3 | 4.9 | nc | (nc-nc) |
| Female | 2 | 2.1 | nc | (nc-nc) | Female | 2 | 3.1 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.6 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) | Female | 2 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 18 | 22.3 | 80.8 | (47.9-127.7) | Female | 1 | 2.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.0 | nc | (nc-nc) | Male | 3 | 3.0 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 8 | 9.1 | 87.4 | (37.7-172.3) | Female | 1 | 2.2 | nc | (nc-nc) |
| Female | 8 | 7.1 | 112.6 | (48.5-222.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 1.8 | nc | (nc-nc) | Male | 31 | 25.9 | 119.5 | (81.2-169.6) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 4 | 3.7 | nc | (nc-nc) | Female | 3 | 4.9 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | Male | 88 | 94.4 | 93.3 | (74.8-114.9) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 64 | 75.2 | 85.1 | (65.6-108.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 2.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 1 | 1.5 | nc | (nc-nc) | Male | 88 | 94.4 | 93.3 | (74.8-114.9) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1.9 | nc | (nc-nc) | Female | 64 | 75.2 | 85.1 | (65.6-108.7) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 14 | 12.1 | 115.2 | (62.9-193.4) | Male | 88 | 94.4 | 93.3 | (74.8-114.9) |
| Female | 14 | 10.2 | 136.7 | (74.7-229.3) | Female | 64 | 75.2 | 85.1 | (65.6-108.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 28 | 34.6 | 81.0 | (53.8-117.0) | Male | 25 | 22.4 | 111.6 | (72.2-164.7) |
| Female | 16 | 12.9 | 124.3 | (71.0-201.9) | Female | 16 | 18.2 | 87.7 | (50.1-142.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 7.0 | 85.2 | (31.1-185.5) | Male | 7 | 5.4 | 128.7 | (51.6-265.2) |
| Female | 6 | 5.7 | 104.7 | (38.2-228.0) | Female | 4 | 4.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 3 | 1.1 | nc | (nc-nc) | Male | 20 | 19.2 | 104.4 | (63.8-161.3) |
| Female | 125 | 127.0 | 98.4 | (81.9-117.3) | Female | 18 | 16.7 | 107.5 | (63.7-169.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 5.6 | nc | (nc-nc) | Male | 6 | 13.4 | 44.7 | (16.3-97.3) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 34 | 46.5 | 73.2 | (50.7-102.2) | Female | 12 | 12.8 | 93.7 | (48.4-163.7) |
| Female | 48 | 45.1 | 106.4 | (78.4-141.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 13 | 10.6 | 122.6 | (65.2-209.6) |
| Male | 6 | 9.0 | 66.3 | (24.2-144.4) | Female | 11 | 11.1 | 99.1 | (49.4-177.3) |
| Female | 1 | 2.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 109 | 128.2 | 85.0 | (69.8-102.6) |
| Male | 4 | 3.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 4 | 2.4 | nc | (nc-nc) | Male | 2 | 8.1 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 4 | 5.0 | nc | (nc-nc) |
| Male | 16 | 17.3 | 92.6 | (52.9-150.4) | <u>Testis</u> | | | | |
| Female | 6 | 10.3 | 58.0 | (21.2-126.2) | Male | 8 | 5.3 | 151.3 | (65.1-298.1) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 5.4 | nc | (nc-nc) | Male | 7 | 6.4 | 109.4 | (43.8-225.4) |
| Female | 4 | 1.5 | nc | (nc-nc) | Female | 20 | 20.8 | 96.0 | (58.6-148.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 12.1 | 57.6 | (23.1-118.7) | Female | 33 | 27.9 | 118.3 | (81.4-166.2) |
| Female | 6 | 9.3 | 64.2 | (23.5-139.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 401 | 462.0 | 86.8 | (78.5-95.7) |
| Male | 6 | 8.6 | 70.0 | (25.6-152.4) | Female | 435 | 445.8 | 97.6 | (88.6-107.2) |
| Female | 1 | 3.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 56 | 62.8 | 89.1 | (67.3-115.7) | | | | | |
| Female | 66 | 61.7 | 107.0 | (82.7-136.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 7 | 6.2 | 113.6 | (45.5-234.0) | Female | 0 | 0.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 1.9 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 0.4 | nc | (nc-nc) |
| Male | 1 | 0.4 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 6 | 5.5 | 108.6 | (39.7-236.5) |
| Male | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.2 | nc | (nc-nc) |
| Male | 0 | 0.8 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.4 | nc | (nc-nc) | Male | 2 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 1 | 1.2 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Female | 3 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 19 | 19.7 | 96.5 | (58.1-150.7) |
| Male | 0 | 0.4 | nc | (nc-nc) | Female | 14 | 18.5 | 75.8 | (41.4-127.2) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 2 | 2.4 | nc | (nc-nc) | | | | | |
| Female | 1 | 2.0 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 27 | 28.2 | 95.8 | (63.1-139.4) | Male | 6 | 16.3 | 36.8 | (13.4-80.2) |
| Female | 14 | 11.1 | 126.3 | (69.0-211.9) | Female | 12 | 12.9 | 93.2 | (48.1-162.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 4.7 | 106.9 | (34.5-249.6) | Male | 2 | 4.3 | nc | (nc-nc) |
| Female | 6 | 4.0 | 148.9 | (54.4-324.0) | Female | 5 | 3.5 | 143.5 | (46.3-335.0) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 15 | 14.1 | 106.2 | (59.4-175.2) |
| Female | 82 | 95.9 | 85.5 | (68.0-106.2) | Female | 15 | 13.7 | 109.2 | (61.1-180.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 7 | 3.5 | 200.9 | (80.5-413.9) | Male | 11 | 9.7 | 113.7 | (56.7-203.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 40 | 36.3 | 110.2 | (78.7-150.0) | Female | 14 | 10.0 | 140.4 | (76.7-235.5) |
| Female | 35 | 38.4 | 91.2 | (63.5-126.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 14 | 8.5 | 165.3 | (90.3-277.3) |
| Male | 8 | 7.0 | 113.7 | (48.9-224.0) | Female | 12 | 9.6 | 124.9 | (64.5-218.2) |
| Female | 3 | 2.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 97 | 101.3 | 95.7 | (77.6-116.8) |
| Male | 4 | 1.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 3 | 1.4 | nc | (nc-nc) | Male | 10 | 6.4 | 155.5 | (74.4-286.0) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 8 | 4.3 | 186.6 | (80.4-367.8) |
| Male | 14 | 12.8 | 109.1 | (59.6-183.1) | <u>Testis</u> | | | | |
| Female | 4 | 8.3 | nc | (nc-nc) | Male | 1 | 2.6 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 4.2 | nc | (nc-nc) | Male | 1 | 4.1 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) | Female | 7 | 12.6 | 55.4 | (22.2-114.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 11 | 8.9 | 123.1 | (61.4-220.3) | Female | 21 | 21.7 | 96.6 | (59.8-147.6) |
| Female | 9 | 7.2 | 124.8 | (56.9-236.9) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 335 | 356.6 | 93.9 | (84.1-104.5) |
| Male | 6 | 6.3 | 94.8 | (34.6-206.3) | Female | 344 | 350.9 | 98.0 | (87.9-109.0) |
| Female | 3 | 2.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 34 | 51.1 | 66.6 | (46.1-93.0) | | | | | |
| Female | 43 | 52.7 | 81.6 | (59.0-109.9) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 46 | 59.8 | 77.0 | (56.3-102.7) | Male | 35 | 40.9 | 85.6 | (59.6-119.0) |
| Female | 29 | 25.2 | 115.1 | (77.1-165.3) | Female | 25 | 38.1 | 65.6 | (42.4-96.8) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 12 | 13.3 | 90.0 | (46.5-157.3) | Male | 5 | 9.4 | 53.3 | (17.2-124.4) |
| Female | 12 | 11.6 | 103.3 | (53.3-180.4) | Female | 10 | 7.9 | 126.8 | (60.7-233.2) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 5 | 1.8 | 278.0 | (89.6-648.7) | Male | 29 | 34.9 | 83.2 | (55.7-119.5) |
| Female | 202 | 239.9 | 84.2 | (73.0-96.6) | Female | 29 | 33.2 | 87.3 | (58.5-125.4) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 10 | 11.7 | 85.6 | (41.0-157.4) | Male | 25 | 23.0 | 108.7 | (70.3-160.5) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 77 | 80.2 | 96.0 | (75.8-120.0) | Female | 13 | 25.0 | 52.1 | (27.7-89.1) |
| Female | 83 | 87.9 | 94.4 | (75.2-117.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 20 | 18.1 | 110.4 | (67.4-170.5) |
| Male | 13 | 15.4 | 84.6 | (45.0-144.7) | Female | 13 | 21.7 | 60.0 | (31.9-102.6) |
| Female | 7 | 4.8 | 147.0 | (58.9-302.9) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 153 | 216.3 | 70.7 | (60.0-82.9) |
| Male | 7 | 8.2 | 85.0 | (34.1-175.2) | <u>Stomach</u> | | | | |
| Female | 8 | 6.7 | 120.1 | (51.7-236.6) | Male | 20 | 14.2 | 141.3 | (86.3-218.2) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 16 | 9.9 | 161.6 | (92.3-262.5) |
| Male | 30 | 29.9 | 100.4 | (67.8-143.4) | <u>Testis</u> | | | | |
| Female | 10 | 19.9 | 50.1 | (24.0-92.2) | Male | 12 | 15.7 | 76.4 | (39.4-133.5) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 12 | 9.1 | 131.2 | (67.7-229.2) | Male | 14 | 12.7 | 110.7 | (60.5-185.7) |
| Female | 5 | 2.9 | 170.3 | (54.9-397.4) | Female | 45 | 45.2 | 99.7 | (72.7-133.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 20 | 22.1 | 90.6 | (55.3-139.9) | Female | 42 | 52.7 | 79.7 | (57.5-107.8) |
| Female | 25 | 18.6 | 134.4 | (86.9-198.4) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 726 | 811.3 | 89.5 | (83.1-96.2) |
| Male | 25 | 14.6 | 171.8 | (111.1-253.6) | Female | 775 | 871.4 | 88.9 | (82.8-95.4) |
| Female | 7 | 5.8 | 120.0 | (48.1-247.3) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 125 | 108.3 | 115.4 | (96.1-137.5) | | | | | |
| Female | 102 | 120.0 | 85.0 | (69.3-103.2) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 29 | 22.4 | 129.5 | (86.7-185.9) | Male | 6 | 12.9 | 46.7 | (17.0-101.6) |
| Female | 10 | 8.8 | 113.7 | (54.4-209.1) | Female | 12 | 10.9 | 109.9 | (56.7-192.0) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 3.7 | 162.3 | (59.3-353.3) | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 3 | 3.5 | nc | (nc-nc) | Female | 4 | 2.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 13 | 11.2 | 115.9 | (61.6-198.1) |
| Female | 91 | 76.6 | 118.9 | (95.7-145.9) | Female | 10 | 11.1 | 90.1 | (43.1-165.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 3.0 | nc | (nc-nc) | Male | 9 | 7.6 | 118.8 | (54.2-225.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 32 | 28.8 | 111.1 | (76.0-156.8) | Female | 10 | 8.1 | 123.3 | (59.0-226.7) |
| Female | 20 | 30.5 | 65.5 | (40.0-101.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 5 | 6.7 | 74.6 | (24.0-174.1) |
| Male | 5 | 5.5 | 90.6 | (29.2-211.4) | Female | 9 | 7.6 | 118.2 | (53.9-224.3) |
| Female | 0 | 1.7 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 86 | 78.6 | 109.4 | (87.5-135.1) |
| Male | 0 | 1.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 1.7 | nc | (nc-nc) | Male | 2 | 5.1 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 4 | 3.4 | nc | (nc-nc) |
| Male | 14 | 10.0 | 139.6 | (76.3-234.2) | <u>Testis</u> | | | | |
| Female | 4 | 6.6 | nc | (nc-nc) | Male | 1 | 2.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 3.3 | nc | (nc-nc) | Male | 1 | 3.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) | Female | 9 | 11.3 | 79.9 | (36.5-151.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 7.1 | 70.1 | (22.6-163.6) | Female | 23 | 17.3 | 133.2 | (84.4-199.9) |
| Female | 6 | 6.0 | 100.8 | (36.8-219.3) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 291 | 280.4 | 103.8 | (92.2-116.4) |
| Male | 2 | 5.0 | nc | (nc-nc) | Female | 284 | 283.0 | 100.4 | (89.0-112.7) |
| Female | 1 | 2.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 48 | 40.0 | 119.9 | (88.4-158.9) | | | | | |
| Female | 37 | 41.6 | 89.0 | (62.6-122.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 5 | 5.7 | 87.8 | (28.3-204.9) | Male | 5 | 4.0 | 126.0 | (40.6-293.9) |
| Female | 4 | 2.0 | nc | (nc-nc) | Female | 3 | 3.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.2 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 4 | 1.0 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 20 | 22.6 | 88.3 | (53.9-136.4) | Female | 4 | 2.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.0 | nc | (nc-nc) | Male | 3 | 2.6 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 5 | 8.0 | 62.3 | (20.1-145.4) | Female | 4 | 2.2 | nc | (nc-nc) |
| Female | 2 | 7.1 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 3 | 1.6 | nc | (nc-nc) | Male | 2 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 2 | 1.7 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 34 | 23.2 | 146.5 | (101.4-204.7) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 0 | 3.1 | nc | (nc-nc) | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 1.0 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 1 | 2.0 | nc | (nc-nc) | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) | Female | 2 | 3.7 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.6 | nc | (nc-nc) | Female | 3 | 5.1 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 6 | 10.6 | 56.8 | (20.8-123.7) | Male | 74 | 80.8 | 91.6 | (71.9-115.0) |
| Female | 7 | 9.9 | 70.8 | (28.4-145.9) | Female | 67 | 75.1 | 89.2 | (69.2-113.3) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 11 | 7.7 | 142.6 | (71.1-255.1) | Male | 14 | 5.7 | 246.3 | (134.6-413.3) |
| Female | 3 | 2.4 | nc | (nc-nc) | Female | 5 | 4.5 | 112.3 | (36.2-262.0) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.9 | nc | (nc-nc) | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) | Female | 2 | 0.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 3 | 4.7 | nc | (nc-nc) |
| Female | 39 | 30.9 | 126.2 | (89.7-172.5) | Female | 2 | 3.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.5 | nc | (nc-nc) | Male | 4 | 3.6 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 16 | 11.0 | 145.4 | (83.1-236.1) | Female | 2 | 2.9 | nc | (nc-nc) |
| Female | 10 | 8.7 | 115.6 | (55.3-212.6) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 7 | 2.5 | 281.9 | (112.9-580.8) |
| Male | 3 | 2.2 | nc | (nc-nc) | Female | 4 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 37 | 32.1 | 115.2 | (81.1-158.7) |
| Male | 1 | 0.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.6 | nc | (nc-nc) | Male | 4 | 1.9 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 0.9 | nc | (nc-nc) |
| Male | 2 | 4.4 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 5 | 2.3 | 218.5 | (70.4-510.0) | Male | 0 | 1.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 1.4 | nc | (nc-nc) | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 7 | 5.7 | 122.5 | (49.1-252.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 6 | 3.0 | 201.3 | (73.5-438.3) | Female | 10 | 6.7 | 149.2 | (71.4-274.3) |
| Female | 1 | 2.0 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 141 | 112.8 | 125.0 | (105.3-147.5) |
| Male | 2 | 2.2 | nc | (nc-nc) | Female | 117 | 99.4 | 117.7 | (97.4-141.1) |
| Female | 0 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 13 | 14.5 | 89.4 | (47.5-152.8) | | | | | |
| Female | 15 | 12.4 | 120.8 | (67.6-199.3) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 25 | 18.8 | 133.2 | (86.2-196.6) | Male | 7 | 11.5 | 60.6 | (24.3-125.0) |
| Female | 8 | 7.6 | 105.6 | (45.5-208.1) | Female | 3 | 9.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 3.6 | nc | (nc-nc) | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 1 | 3.1 | nc | (nc-nc) | Female | 0 | 2.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 8 | 10.1 | 79.5 | (34.2-156.7) |
| Female | 52 | 68.2 | 76.3 | (57.0-100.0) | Female | 8 | 9.7 | 82.5 | (35.5-162.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 2.8 | nc | (nc-nc) | Male | 5 | 6.7 | 74.1 | (23.9-173.0) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 36 | 24.7 | 145.8 | (102.1-201.8) | Female | 3 | 7.1 | nc | (nc-nc) |
| Female | 26 | 26.8 | 97.1 | (63.4-142.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 7 | 5.6 | 123.9 | (49.6-255.3) |
| Male | 3 | 4.7 | nc | (nc-nc) | Female | 3 | 6.6 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 44 | 65.8 | 66.9 | (48.6-89.8) |
| Male | 1 | 1.7 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 1.4 | nc | (nc-nc) | Male | 4 | 4.4 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 3.0 | nc | (nc-nc) |
| Male | 6 | 8.8 | 68.0 | (24.8-148.0) | <u>Testis</u> | | | | |
| Female | 6 | 5.8 | 104.2 | (38.0-226.7) | Male | 2 | 2.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 2.8 | 180.2 | (58.1-420.4) | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) | Female | 5 | 10.5 | 47.6 | (15.3-111.0) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 6.5 | 122.9 | (52.9-242.3) | Female | 20 | 15.0 | 133.8 | (81.7-206.6) |
| Female | 8 | 5.3 | 149.6 | (64.4-294.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 212 | 241.8 | 87.7 | (76.3-100.3) |
| Male | 2 | 4.4 | nc | (nc-nc) | Female | 200 | 249.0 | 80.3 | (69.6-92.3) |
| Female | 1 | 1.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 28 | 33.4 | 83.8 | (55.7-121.1) | | | | | |
| Female | 28 | 35.5 | 78.8 | (52.4-113.9) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 9 | 9.7 | 92.8 | (42.4-176.3) | Male | 2 | 6.4 | nc | (nc-nc) |
| Female | 3 | 3.3 | nc | (nc-nc) | Female | 1 | 4.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 2.0 | nc | (nc-nc) | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) | Female | 1 | 1.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Male | 9 | 5.5 | 163.9 | (74.8-311.2) |
| Female | 46 | 34.7 | 132.7 | (97.1-177.0) | Female | 4 | 4.4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.5 | nc | (nc-nc) | Male | 4 | 3.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 15 | 13.2 | 114.0 | (63.7-188.0) | Female | 4 | 3.4 | nc | (nc-nc) |
| Female | 23 | 11.6 | 198.5 | (125.8-297.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 5 | 3.0 | 167.5 | (54.0-391.0) |
| Male | 4 | 2.6 | nc | (nc-nc) | Female | 1 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 39 | 35.9 | 108.7 | (77.3-148.6) |
| Male | 3 | 0.9 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Male | 4 | 2.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 2 | 1.3 | nc | (nc-nc) |
| Male | 3 | 4.9 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 2 | 2.8 | nc | (nc-nc) | Male | 2 | 1.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 1.5 | nc | (nc-nc) | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 5 | 5.7 | 87.4 | (28.2-203.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 3 | 3.4 | nc | (nc-nc) | Female | 9 | 7.6 | 118.2 | (53.9-224.3) |
| Female | 1 | 2.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 142 | 130.5 | 108.8 | (91.7-128.3) |
| Male | 3 | 2.5 | nc | (nc-nc) | Female | 128 | 118.9 | 107.7 | (89.8-128.0) |
| Female | 1 | 0.8 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 18 | 17.5 | 102.6 | (60.8-162.2) | | | | | |
| Female | 18 | 16.3 | 110.2 | (65.3-174.2) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 10 | 12.8 | 78.3 | (37.5-143.9) | Male | 7 | 8.3 | 84.2 | (33.7-173.5) |
| Female | 4 | 4.2 | nc | (nc-nc) | Female | 3 | 6.3 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 2.6 | nc | (nc-nc) | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 3 | 2.0 | nc | (nc-nc) | Female | 0 | 1.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 10 | 7.1 | 140.8 | (67.4-259.0) |
| Female | 40 | 44.7 | 89.6 | (64.0-122.0) | Female | 10 | 5.7 | 176.9 | (84.7-325.4) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.9 | nc | (nc-nc) | Male | 2 | 5.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 19 | 17.3 | 109.6 | (65.9-171.1) | Female | 4 | 4.5 | nc | (nc-nc) |
| Female | 21 | 14.7 | 142.4 | (88.1-217.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 4.0 | nc | (nc-nc) |
| Male | 1 | 3.4 | nc | (nc-nc) | Female | 4 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 38 | 49.1 | 77.4 | (54.8-106.3) |
| Male | 0 | 1.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.9 | nc | (nc-nc) | Male | 0 | 3.0 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 1.6 | nc | (nc-nc) |
| Male | 3 | 6.5 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 7 | 3.6 | 196.0 | (78.5-403.9) | Male | 0 | 1.9 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 2.0 | 244.0 | (78.6-569.3) | Male | 5 | 2.4 | 211.2 | (68.1-492.8) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 5 | 7.3 | 68.3 | (22.0-159.5) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 4.5 | nc | (nc-nc) | Female | 10 | 10.0 | 100.4 | (48.0-184.6) |
| Female | 3 | 3.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 146 | 173.4 | 84.2 | (71.1-99.0) |
| Male | 3 | 3.3 | nc | (nc-nc) | Female | 153 | 152.8 | 100.1 | (84.9-117.3) |
| Female | 0 | 1.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 23 | 23.5 | 97.8 | (62.0-146.8) | | | | | |
| Female | 21 | 21.1 | 99.6 | (61.6-152.3) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 93 | 139.9 | 66.5 | (53.7-81.4) | Male | 38 | 87.7 | 43.3 | (30.6-59.4) |
| Female | 42 | 56.3 | 74.6 | (53.8-100.8) | Female | 36 | 79.1 | 45.5 | (31.9-63.0) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 18 | 28.8 | 62.5 | (37.0-98.8) | Male | 19 | 21.5 | 88.3 | (53.2-138.0) |
| Female | 19 | 25.9 | 73.5 | (44.2-114.8) | Female | 17 | 17.8 | 95.4 | (55.5-152.8) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 7 | 4.2 | 168.2 | (67.4-346.6) | Male | 51 | 76.6 | 66.5 | (49.5-87.5) |
| Female | 503 | 537.6 | 93.6 | (85.6-102.1) | Female | 63 | 73.3 | 85.9 | (66.0-109.9) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 37 | 23.5 | 157.5 | (110.9-217.1) | Male | 62 | 50.9 | 121.8 | (93.4-156.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 159 | 184.2 | 86.3 | (73.4-100.8) | Female | 40 | 55.3 | 72.4 | (51.7-98.6) |
| Female | 153 | 196.1 | 78.0 | (66.1-91.4) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 42 | 42.2 | 99.5 | (71.7-134.6) |
| Male | 31 | 35.2 | 88.0 | (59.8-125.0) | Female | 35 | 48.6 | 71.9 | (50.1-100.1) |
| Female | 7 | 10.7 | 65.4 | (26.2-134.7) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 446 | 494.8 | 90.1 | (82.0-98.9) |
| Male | 17 | 14.3 | 119.3 | (69.4-191.0) | <u>Stomach</u> | | | | |
| Female | 10 | 12.2 | 81.8 | (39.1-150.4) | Male | 56 | 32.6 | 171.9 | (129.9-223.3) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 27 | 21.8 | 123.6 | (81.4-179.8) |
| Male | 76 | 66.7 | 114.0 | (89.8-142.7) | <u>Testis</u> | | | | |
| Female | 44 | 44.8 | 98.3 | (71.4-132.0) | Male | 18 | 23.2 | 77.7 | (46.0-122.8) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 25 | 20.9 | 119.9 | (77.6-177.0) | Male | 12 | 24.6 | 48.9 | (25.2-85.4) |
| Female | 7 | 6.5 | 107.1 | (42.9-220.7) | Female | 68 | 89.3 | 76.2 | (59.1-96.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 32 | 50.4 | 63.5 | (43.4-89.6) | Female | 118 | 118.5 | 99.6 | (82.4-119.2) |
| Female | 31 | 41.7 | 74.4 | (50.5-105.6) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 1610 | 1826.5 | 88.1 | (83.9-92.6) |
| Male | 33 | 32.8 | 100.7 | (69.3-141.4) | Female | 1712 | 1925.9 | 88.9 | (84.7-93.2) |
| Female | 13 | 13.0 | 99.7 | (53.0-170.4) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 255 | 251.1 | 101.6 | (89.5-114.8) | | | | | |
| Female | 261 | 270.3 | 96.6 | (85.2-109.0) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 11 | 7.2 | 152.5 | (76.0-272.9) | Male | 6 | 5.1 | 118.1 | (43.1-257.0) |
| Female | 2 | 2.2 | nc | (nc-nc) | Female | 4 | 3.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.6 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 7 | 4.3 | 163.3 | (65.4-336.4) |
| Female | 27 | 27.1 | 99.7 | (65.7-145.0) | Female | 3 | 3.1 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.3 | nc | (nc-nc) | Male | 3 | 3.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 4 | 10.2 | nc | (nc-nc) | Female | 4 | 2.6 | nc | (nc-nc) |
| Female | 6 | 7.7 | 77.5 | (28.3-168.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 2.3 | nc | (nc-nc) |
| Male | 0 | 2.1 | nc | (nc-nc) | Female | 4 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 24 | 29.2 | 82.3 | (52.7-122.4) |
| Male | 0 | 0.7 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 3 | 1.7 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 0.8 | nc | (nc-nc) |
| Male | 6 | 4.0 | 150.1 | (54.8-326.6) | <u>Testis</u> | | | | |
| Female | 5 | 2.0 | 249.6 | (80.4-582.5) | Male | 0 | 1.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 1.2 | nc | (nc-nc) | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 2 | 4.8 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 2.6 | nc | (nc-nc) | Female | 4 | 5.9 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 85 | 102.7 | 82.7 | (66.1-102.3) |
| Male | 0 | 2.1 | nc | (nc-nc) | Female | 81 | 87.0 | 93.1 | (73.9-115.7) |
| Female | 0 | 0.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 10 | 13.5 | 74.2 | (35.5-136.4) | | | | | |
| Female | 9 | 10.9 | 82.5 | (37.6-156.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 4.3 | nc | (nc-nc) | Male | 4 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) | Female | 2 | 1.7 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 8 | 12.8 | 62.7 | (27.0-123.6) | Female | 2 | 1.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 0.4 | nc | (nc-nc) | Male | 0 | 1.4 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 5.5 | nc | (nc-nc) | Female | 4 | 1.3 | nc | (nc-nc) |
| Female | 1 | 4.8 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 1.3 | nc | (nc-nc) |
| Male | 0 | 1.1 | nc | (nc-nc) | Female | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 10 | 14.8 | 67.4 | (32.3-123.9) |
| Male | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 1.0 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.5 | nc | (nc-nc) |
| Male | 1 | 1.9 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 1.1 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 3 | 1.6 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Female | 2 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 35 | 52.8 | 66.3 | (46.2-92.2) |
| Male | 0 | 0.9 | nc | (nc-nc) | Female | 31 | 45.5 | 68.2 | (46.3-96.8) |
| Female | 0 | 0.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 7 | 7.7 | 91.0 | (36.5-187.5) | | | | | |
| Female | 5 | 6.8 | 73.1 | (23.6-170.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 38 | 30.4 | 125.2 | (88.6-171.8) | Male | 11 | 17.8 | 61.9 | (30.8-110.7) |
| Female | 8 | 11.8 | 67.5 | (29.1-133.0) | Female | 11 | 14.3 | 77.1 | (38.5-138.0) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 7 | 5.2 | 134.5 | (53.9-277.1) | Male | 4 | 4.6 | nc | (nc-nc) |
| Female | 3 | 4.5 | nc | (nc-nc) | Female | 1 | 3.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | Male | 18 | 15.4 | 116.6 | (69.1-184.3) |
| Female | 112 | 103.7 | 108.0 | (88.9-130.0) | Female | 11 | 14.7 | 74.6 | (37.2-133.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 7 | 4.0 | 176.0 | (70.5-362.6) | Male | 11 | 10.4 | 105.6 | (52.6-188.9) |
| <u>Colon / Rectum</u> | | | | | Female | 11 | 5.4 | 205.4 | (102.4-367.6) |
| Male | 41 | 39.3 | 104.4 | (74.9-141.6) | <u>Ovary</u> | | | | |
| Female | 49 | 41.2 | 118.8 | (87.9-157.1) | Female | 15 | 10.7 | 139.8 | (78.2-230.6) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 9 | 7.5 | 120.1 | (54.8-228.0) | Male | 9 | 9.1 | 99.1 | (45.2-188.1) |
| Female | 3 | 2.3 | nc | (nc-nc) | Female | 12 | 10.3 | 116.6 | (60.2-203.7) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 2 | 2.1 | nc | (nc-nc) | Male | 113 | 106.5 | 106.1 | (87.5-127.6) |
| Female | 3 | 1.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | 8 | 7.0 | 114.6 | (49.3-225.8) |
| Male | 20 | 13.8 | 144.8 | (88.4-223.6) | Female | 5 | 4.6 | 107.8 | (34.8-251.7) |
| Female | 7 | 8.9 | 78.9 | (31.6-162.6) | <u>Testis</u> | | | | |
| <u>Larynx</u> | | | | | Male | 6 | 3.2 | 188.6 | (68.9-410.4) |
| Male | 6 | 4.4 | 135.0 | (49.3-293.9) | <u>Thyroid</u> | | | | |
| Female | 4 | 1.3 | nc | (nc-nc) | Male | 1 | 4.5 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | Female | 15 | 14.5 | 103.6 | (58.0-170.9) |
| Male | 13 | 9.8 | 132.2 | (70.3-226.0) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Female | 9 | 7.9 | 113.5 | (51.8-215.6) | Female | 20 | 23.0 | 87.0 | (53.1-134.3) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 10 | 6.8 | 146.9 | (70.3-270.1) | Male | 427 | 382.7 | 111.6 | (101.2-122.7) |
| Female | 3 | 2.6 | nc | (nc-nc) | Female | 409 | 378.8 | 108.0 | (97.8-119.0) |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 64 | 54.3 | 117.9 | (90.8-150.5) | | | | | |
| Female | 67 | 56.0 | 119.7 | (92.8-152.0) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 37 | 31.5 | 117.6 | (82.8-162.1) | Male | 21 | 19.7 | 106.7 | (66.0-163.0) |
| Female | 14 | 12.2 | 114.6 | (62.6-192.2) | Female | 14 | 16.2 | 86.4 | (47.2-145.0) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 6.0 | 83.3 | (26.8-194.4) | Male | 11 | 4.9 | 223.9 | (111.6-400.7) |
| Female | 5 | 5.0 | 99.3 | (32.0-231.6) | Female | 4 | 3.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 1.0 | nc | (nc-nc) | Male | 20 | 16.9 | 118.4 | (72.3-182.8) |
| Female | 109 | 117.6 | 92.7 | (76.1-111.8) | Female | 13 | 15.6 | 83.1 | (44.2-142.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 8 | 4.7 | 169.4 | (72.9-333.8) | Male | 19 | 12.0 | 158.2 | (95.2-247.1) |
| Female | 8 | 4.7 | 169.4 | (72.9-333.8) | Female | 8 | 5.9 | 135.9 | (58.5-267.8) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 51 | 41.9 | 121.8 | (90.7-160.1) | Female | 21 | 11.9 | 176.1 | (109.0-269.2) |
| Female | 52 | 42.3 | 123.1 | (91.9-161.4) | Female | 21 | 11.9 | 176.1 | (109.0-269.2) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 20 | 8.2 | 242.7 | (148.2-374.8) | Male | 15 | 9.7 | 155.4 | (86.9-256.3) |
| Female | 3 | 2.3 | nc | (nc-nc) | Female | 8 | 10.5 | 76.0 | (32.7-149.7) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 2 | 2.5 | nc | (nc-nc) | Male | 112 | 118.0 | 94.9 | (78.1-114.2) |
| Female | 4 | 2.0 | nc | (nc-nc) | Male | 112 | 118.0 | 94.9 | (78.1-114.2) |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Stomach</u> | | | | |
| Male | 9 | 15.4 | 58.4 | (26.7-110.9) | Male | 7 | 7.3 | 95.9 | (38.4-197.6) |
| Female | 13 | 9.7 | 133.9 | (71.2-229.0) | Female | 3 | 4.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 8 | 4.9 | 162.6 | (70.0-320.4) | Male | 6 | 4.0 | 151.3 | (55.3-329.4) |
| Female | 1 | 1.4 | nc | (nc-nc) | Male | 6 | 4.0 | 151.3 | (55.3-329.4) |
| <u>Leukemia</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 10 | 10.6 | 94.0 | (45.0-172.8) | Male | 10 | 5.4 | 185.7 | (88.9-341.6) |
| Female | 7 | 8.4 | 83.4 | (33.4-171.9) | Female | 21 | 17.6 | 119.3 | (73.8-182.4) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 7.7 | 64.7 | (20.8-151.0) | Female | 24 | 26.5 | 90.6 | (58.0-134.8) |
| Female | 4 | 2.8 | nc | (nc-nc) | Female | 24 | 26.5 | 90.6 | (58.0-134.8) |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 68 | 57.6 | 118.0 | (91.6-149.6) | Male | 467 | 416.6 | 112.1 | (102.2-122.7) |
| Female | 71 | 59.3 | 119.7 | (93.5-150.9) | Female | 453 | 413.8 | 109.5 | (99.6-120.0) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 7 | 5.3 | 133.2 | (53.3-274.4) | Male | 7 | 3.9 | 177.5 | (71.1-365.7) |
| Female | 3 | 1.8 | nc | (nc-nc) | Female | 10 | 3.2 | 316.6 | (151.6-582.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 1.3 | nc | (nc-nc) | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 5 | 3.3 | 153.5 | (49.5-358.2) |
| Female | 32 | 22.8 | 140.5 | (96.1-198.3) | Female | 1 | 2.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.0 | nc | (nc-nc) | Male | 3 | 2.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 7.7 | nc | (nc-nc) | Female | 0 | 2.2 | nc | (nc-nc) |
| Female | 8 | 6.4 | 124.6 | (53.6-245.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 1 | 1.6 | nc | (nc-nc) | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | Female | 2 | 1.5 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 32 | 23.7 | 135.3 | (92.5-190.9) |
| Female | 2 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 1 | 3.2 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 1.0 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 0 | 2.0 | nc | (nc-nc) | Male | 3 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) | Female | 1 | 3.9 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1.6 | nc | (nc-nc) | Female | 4 | 5.1 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 6 | 10.2 | 59.0 | (21.6-128.5) | Male | 81 | 79.6 | 101.7 | (80.8-126.5) |
| Female | 7 | 9.3 | 75.6 | (30.3-155.8) | Female | 84 | 72.9 | 115.3 | (91.9-142.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 8 | 10.2 | 78.1 | (33.6-154.0) | Male | 2 | 6.5 | nc | (nc-nc) |
| Female | 3 | 3.4 | nc | (nc-nc) | Female | 4 | 4.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 2.0 | nc | (nc-nc) | Male | 0 | 1.6 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) | Female | 1 | 1.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 34 | 35.1 | 96.9 | (67.1-135.4) | Female | 5 | 4.5 | 112.2 | (36.2-261.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 1.5 | nc | (nc-nc) | Male | 1 | 4.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 15 | 13.8 | 109.1 | (61.0-179.9) | Female | 1 | 3.5 | nc | (nc-nc) |
| Female | 12 | 11.8 | 102.0 | (52.6-178.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 3 | 3.2 | nc | (nc-nc) |
| Male | 3 | 2.7 | nc | (nc-nc) | Female | 4 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 30 | 39.1 | 76.7 | (51.7-109.5) |
| Male | 0 | 0.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.6 | nc | (nc-nc) | Male | 4 | 2.4 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 1.3 | nc | (nc-nc) |
| Male | 2 | 5.2 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 2 | 2.8 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 1.6 | nc | (nc-nc) | Male | 4 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 8 | 5.5 | 144.3 | (62.1-284.3) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 3.5 | nc | (nc-nc) | Female | 8 | 7.8 | 102.3 | (44.1-201.6) |
| Female | 4 | 2.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 105 | 137.3 | 76.5 | (62.5-92.6) |
| Male | 1 | 2.6 | nc | (nc-nc) | Female | 123 | 120.2 | 102.3 | (85.0-122.0) |
| Female | 1 | 0.8 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 15 | 18.8 | 79.7 | (44.6-131.5) | | | | | |
| Female | 18 | 16.8 | 107.2 | (63.5-169.4) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 18 | 16.0 | 112.7 | (66.8-178.1) | Male | 14 | 11.2 | 125.2 | (68.4-210.1) |
| Female | 7 | 5.3 | 131.0 | (52.5-270.0) | Female | 9 | 8.6 | 104.2 | (47.5-197.8) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 3.6 | 137.5 | (44.3-320.8) | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 5 | 2.7 | 182.0 | (58.7-424.8) | Female | 3 | 1.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 12 | 9.4 | 128.0 | (66.1-223.6) |
| Female | 76 | 63.0 | 120.5 | (95.0-150.9) | Female | 10 | 7.3 | 137.4 | (65.8-252.7) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 2.8 | nc | (nc-nc) | Male | 4 | 7.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 29 | 22.5 | 128.9 | (86.3-185.1) | Female | 2 | 6.1 | nc | (nc-nc) |
| Female | 22 | 18.9 | 116.6 | (73.0-176.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 5.1 | nc | (nc-nc) |
| Male | 1 | 4.6 | nc | (nc-nc) | Female | 3 | 4.6 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 71 | 66.4 | 106.9 | (83.4-134.8) |
| Male | 2 | 1.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 1.1 | nc | (nc-nc) | Male | 4 | 3.8 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 2.0 | nc | (nc-nc) |
| Male | 6 | 8.9 | 67.7 | (24.7-147.4) | <u>Testis</u> | | | | |
| Female | 4 | 4.7 | nc | (nc-nc) | Male | 1 | 2.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 2.8 | nc | (nc-nc) | Male | 7 | 3.4 | 208.2 | (83.4-428.9) |
| Female | 1 | 0.7 | nc | (nc-nc) | Female | 9 | 10.5 | 86.1 | (39.3-163.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 5.9 | 119.0 | (47.7-245.3) | Female | 14 | 13.9 | 100.6 | (55.0-168.8) |
| Female | 6 | 4.1 | 145.1 | (53.0-315.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 229 | 228.9 | 100.0 | (87.5-113.9) |
| Male | 3 | 4.6 | nc | (nc-nc) | Female | 211 | 205.2 | 102.8 | (89.4-117.7) |
| Female | 1 | 1.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 20 | 30.2 | 66.2 | (40.4-102.2) | | | | | |
| Female | 17 | 26.5 | 64.1 | (37.3-102.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 3 | 2.3 | nc | (nc-nc) | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) | Female | 0 | 1.7 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 0.6 | nc | (nc-nc) | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 8 | 9.9 | 80.8 | (34.8-159.1) | Female | 1 | 1.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 1 | 1.0 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 1 | 3.3 | nc | (nc-nc) | Female | 1 | 1.0 | nc | (nc-nc) |
| Female | 4 | 3.5 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 0.8 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 11 | 8.9 | 123.5 | (61.5-220.9) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 0 | 2.1 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Female | 2 | 2.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 1 | 4.3 | nc | (nc-nc) | Male | 29 | 33.7 | 86.0 | (57.6-123.6) |
| Female | 1 | 4.5 | nc | (nc-nc) | Female | 25 | 35.4 | 70.6 | (45.6-104.2) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 4 | 7.6 | nc | (nc-nc) | Male | 3 | 5.5 | nc | (nc-nc) |
| Female | 3 | 2.3 | nc | (nc-nc) | Female | 1 | 4.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.8 | nc | (nc-nc) | Male | 4 | 1.3 | nc | (nc-nc) |
| Female | 3 | 1.3 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 8 | 4.6 | 172.5 | (74.3-339.8) |
| Female | 27 | 28.9 | 93.4 | (61.5-135.9) | Female | 2 | 3.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.4 | nc | (nc-nc) | Male | 4 | 3.6 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 7 | 10.9 | 64.0 | (25.6-131.8) | Female | 3 | 2.8 | nc | (nc-nc) |
| Female | 6 | 8.1 | 74.4 | (27.2-162.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 2.2 | nc | (nc-nc) | Male | 30 | 31.6 | 94.9 | (64.0-135.5) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Male | 3 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 4 | 4.3 | nc | (nc-nc) | Female | 2 | 6.4 | nc | (nc-nc) |
| Female | 4 | 2.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 1.3 | nc | (nc-nc) | Male | 101 | 110.7 | 91.2 | (74.3-110.8) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 95 | 93.0 | 102.1 | (82.6-124.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 2.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 3 | 1.9 | nc | (nc-nc) | Male | 101 | 110.7 | 91.2 | (74.3-110.8) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 2.3 | nc | (nc-nc) | Female | 95 | 93.0 | 102.1 | (82.6-124.9) |
| Female | 0 | 0.6 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 11 | 14.2 | 77.4 | (38.6-138.5) | Male | 101 | 110.7 | 91.2 | (74.3-110.8) |
| Female | 24 | 11.6 | 206.2 | (132.1-306.9) | Female | 95 | 93.0 | 102.1 | (82.6-124.9) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|--------------|----------------------|--|------------|------------|--------------|----------------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 17 | 20.2 | 84.3 | (49.1-135.0) | Male | 17 | 11.7 | 145.2 | (84.5-232.5) |
| Female | 11 | 7.7 | 142.0 | (70.8-254.1) | Female | 20 | 9.5 | 210.8 | (128.7-325.6) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 3.4 | nc | (nc-nc) | Male | 6 | 3.1 | 196.7 | (71.8-428.1) |
| Female | 4 | 3.0 | nc | (nc-nc) | Female | 0 | 2.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 16 | 10.2 | 156.1 | (89.2-253.5) |
| Female | 75 | 69.0 | 108.7 | (85.5-136.2) | Female | 12 | 9.7 | 123.1 | (63.5-215.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 2.7 | nc | (nc-nc) | Male | 1 | 6.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 28 | 26.2 | 106.8 | (71.0-154.4) | Female | 8 | 7.1 | 112.5 | (48.4-221.7) |
| Female | 26 | 27.8 | 93.5 | (61.1-137.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 8 | 6.0 | 133.1 | (57.3-262.3) |
| Male | 1 | 4.9 | nc | (nc-nc) | Female | 5 | 6.8 | 73.1 | (23.6-170.6) |
| Female | 1 | 1.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 69 | 68.2 | 101.1 | (78.7-128.0) |
| Male | 2 | 1.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.1 | nc | (nc-nc) | Male | 3 | 4.7 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 3 | 3.1 | nc | (nc-nc) |
| Male | 8 | 9.0 | 88.8 | (38.2-175.0) | <u>Testis</u> | | | | |
| Female | 2 | 5.8 | nc | (nc-nc) | Male | 2 | 1.9 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 2.9 | nc | (nc-nc) | Male | 7 | 2.9 | 239.2 | (95.8-492.9) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 8 | 9.6 | 83.5 | (36.0-164.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 15 | 6.6 | 227.5 | (127.3-375.3) | Female | 20 | 15.1 | 132.7 | (81.0-205.0) |
| Female | 5 | 5.3 | 94.2 | (30.4-219.9) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 260 | 250.2 | 103.9 | (91.7-117.4) |
| Male | 2 | 4.5 | nc | (nc-nc) | Female | 254 | 250.3 | 101.5 | (89.4-114.7) |
| Female | 1 | 1.8 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 27 | 35.1 | 77.0 | (50.7-112.0) | | | | | |
| Female | 27 | 35.7 | 75.6 | (49.8-110.0) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 26 | 20.5 | 126.8 | (82.8-185.8) | Male | 14 | 12.7 | 110.0 | (60.1-184.6) |
| Female | 12 | 7.4 | 161.8 | (83.5-282.6) | Female | 9 | 9.8 | 91.6 | (41.8-173.9) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 3.8 | 131.1 | (42.2-305.9) | Male | 2 | 3.2 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) | Female | 0 | 2.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 9 | 10.9 | 82.3 | (37.5-156.2) |
| Female | 60 | 71.6 | 83.8 | (64.0-107.9) | Female | 11 | 9.5 | 115.8 | (57.7-207.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 2 | 2.8 | nc | (nc-nc) | Male | 7 | 7.8 | 90.1 | (36.1-185.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 25 | 27.3 | 91.6 | (59.3-135.2) | Female | 6 | 7.2 | 82.8 | (30.2-180.2) |
| Female | 35 | 25.7 | 136.0 | (94.7-189.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 7 | 6.3 | 111.6 | (44.7-229.9) |
| Male | 5 | 5.3 | 93.7 | (30.2-218.8) | Female | 8 | 6.4 | 124.6 | (53.7-245.5) |
| Female | 1 | 1.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 87 | 76.1 | 114.3 | (91.6-141.0) |
| Male | 2 | 1.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 1.2 | nc | (nc-nc) | Male | 3 | 4.8 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 3 | 2.8 | nc | (nc-nc) |
| Male | 8 | 9.9 | 80.5 | (34.6-158.6) | <u>Testis</u> | | | | |
| Female | 10 | 5.9 | 169.6 | (81.2-312.0) | Male | 4 | 2.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 3.2 | 157.4 | (50.7-367.2) | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 11 | 10.6 | 103.5 | (51.6-185.3) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 6.9 | nc | (nc-nc) | Female | 15 | 16.1 | 93.3 | (52.2-153.9) |
| Female | 6 | 5.0 | 118.9 | (43.4-258.7) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 293 | 269.5 | 108.7 | (96.6-121.9) |
| Male | 2 | 5.0 | nc | (nc-nc) | Female | 252 | 251.3 | 100.3 | (88.3-113.5) |
| Female | 3 | 1.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 51 | 37.3 | 136.8 | (101.9-179.9) | | | | | |
| Female | 29 | 36.1 | 80.4 | (53.8-115.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 58 | 55.1 | 105.3 | (79.9-136.1) | Male | 18 | 35.7 | 50.4 | (29.8-79.6) |
| Female | 17 | 21.8 | 78.0 | (45.4-124.9) | Female | 19 | 30.7 | 62.0 | (37.3-96.8) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 12 | 11.3 | 105.9 | (54.7-185.1) | Male | 12 | 8.6 | 139.1 | (71.8-243.0) |
| Female | 10 | 9.7 | 103.3 | (49.4-189.9) | Female | 6 | 6.9 | 87.0 | (31.8-189.4) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 1.7 | nc | (nc-nc) | Male | 29 | 30.6 | 94.7 | (63.4-136.1) |
| Female | 194 | 209.8 | 92.4 | (79.9-106.4) | Female | 28 | 28.4 | 98.5 | (65.5-142.4) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 13 | 9.2 | 140.8 | (74.9-240.8) | Male | 26 | 21.2 | 122.7 | (80.1-179.8) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 74 | 73.7 | 100.5 | (78.9-126.1) | Female | 19 | 21.4 | 88.8 | (53.4-138.6) |
| Female | 75 | 76.4 | 98.1 | (77.2-123.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 25 | 16.9 | 148.3 | (95.9-218.9) |
| Male | 12 | 14.4 | 83.5 | (43.1-145.9) | Female | 21 | 18.8 | 111.5 | (69.0-170.4) |
| Female | 3 | 4.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 189 | 204.4 | 92.4 | (79.7-106.6) |
| Male | 7 | 5.4 | 130.6 | (52.3-269.0) | <u>Stomach</u> | | | | |
| Female | 6 | 4.4 | 137.7 | (50.3-299.6) | Male | 20 | 12.9 | 154.9 | (94.6-239.2) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 12 | 8.5 | 140.4 | (72.5-245.4) |
| Male | 35 | 27.4 | 127.8 | (89.0-177.8) | <u>Testis</u> | | | | |
| Female | 18 | 17.3 | 104.1 | (61.7-164.6) | Male | 7 | 9.2 | 76.4 | (30.6-157.4) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 12 | 8.6 | 139.9 | (72.2-244.5) | Male | 7 | 10.3 | 68.3 | (27.3-140.7) |
| Female | 1 | 2.5 | nc | (nc-nc) | Female | 29 | 34.6 | 83.7 | (56.1-120.3) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 12 | 19.5 | 61.7 | (31.8-107.8) | Female | 34 | 46.2 | 73.5 | (50.9-102.8) |
| Female | 10 | 15.9 | 63.0 | (30.2-115.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 773 | 737.0 | 104.9 | (97.6-112.5) |
| Male | 17 | 13.5 | 126.1 | (73.4-201.9) | Female | 706 | 747.0 | 94.5 | (87.7-101.7) |
| Female | 4 | 5.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 133 | 100.4 | 132.4 | (110.9-156.9) | | | | | |
| Female | 129 | 104.1 | 123.9 | (103.4-147.2) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 7 | 7.9 | 88.4 | (35.4-182.1) | Male | 8 | 5.2 | 152.5 | (65.7-300.5) |
| Female | 2 | 2.8 | nc | (nc-nc) | Female | 0 | 3.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 1.6 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | Female | 1 | 0.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 4.5 | nc | (nc-nc) |
| Female | 32 | 27.5 | 116.5 | (79.7-164.4) | Female | 2 | 3.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.2 | nc | (nc-nc) | Male | 2 | 3.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 7 | 10.8 | 64.6 | (25.9-133.2) | Female | 7 | 2.8 | 252.9 | (101.3-521.2) |
| Female | 8 | 9.6 | 82.9 | (35.7-163.4) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 2.5 | nc | (nc-nc) |
| Male | 5 | 2.2 | 231.4 | (74.6-540.0) | Female | 0 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 30 | 30.9 | 97.0 | (65.4-138.5) |
| Male | 0 | 0.7 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.5 | nc | (nc-nc) | Male | 2 | 1.9 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 3 | 1.1 | nc | (nc-nc) |
| Male | 2 | 4.1 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 3 | 2.2 | nc | (nc-nc) | Male | 0 | 1.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 1.3 | nc | (nc-nc) | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 2 | 0.3 | nc | (nc-nc) | Female | 2 | 4.4 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 2.8 | 179.7 | (57.9-419.4) | Female | 10 | 6.0 | 165.5 | (79.2-304.4) |
| Female | 3 | 2.0 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 95 | 108.7 | 87.4 | (70.7-106.8) |
| Male | 0 | 2.1 | nc | (nc-nc) | Female | 92 | 95.8 | 96.1 | (77.4-117.8) |
| Female | 0 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 18 | 14.7 | 122.6 | (72.6-193.8) | | | | | |
| Female | 8 | 13.3 | 60.3 | (26.0-118.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 23 | 29.2 | 78.7 | (49.9-118.1) | Male | 17 | 19.7 | 86.3 | (50.2-138.2) |
| Female | 19 | 10.4 | 182.5 | (109.8-285.0) | Female | 14 | 15.6 | 89.7 | (49.0-150.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 6.2 | nc | (nc-nc) | Male | 7 | 4.7 | 148.7 | (59.6-306.4) |
| Female | 4 | 4.9 | nc | (nc-nc) | Female | 2 | 3.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 0.9 | nc | (nc-nc) | Male | 12 | 16.6 | 72.3 | (37.3-126.3) |
| Female | 104 | 112.0 | 92.9 | (75.9-112.5) | Female | 16 | 13.8 | 116.0 | (66.3-188.4) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 7 | 4.9 | 143.3 | (57.4-295.2) | Male | 16 | 12.3 | 130.6 | (74.6-212.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 43 | 40.0 | 107.5 | (77.8-144.7) | Female | 15 | 11.1 | 135.6 | (75.8-223.7) |
| Female | 35 | 35.7 | 98.1 | (68.3-136.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 21 | 9.1 | 229.6 | (142.1-351.0) |
| Male | 8 | 8.0 | 99.6 | (42.9-196.4) | Female | 15 | 8.8 | 169.9 | (95.0-280.2) |
| Female | 0 | 2.0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 116 | 116.7 | 99.4 | (82.1-119.2) |
| Male | 4 | 2.7 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 2.0 | nc | (nc-nc) | Male | 3 | 6.9 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 6 | 3.9 | 155.2 | (56.7-337.8) |
| Male | 16 | 15.4 | 104.1 | (59.5-169.1) | <u>Testis</u> | | | | |
| Female | 13 | 8.9 | 146.2 | (77.8-250.1) | Male | 3 | 4.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 4.8 | nc | (nc-nc) | Male | 5 | 5.8 | 86.6 | (27.9-202.1) |
| Female | 1 | 1.3 | nc | (nc-nc) | Female | 29 | 18.4 | 157.5 | (105.5-226.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 10.4 | 48.2 | (15.5-112.4) | Female | 28 | 25.2 | 111.0 | (73.7-160.4) |
| Female | 17 | 7.6 | 225.1 | (131.1-360.5) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 415 | 406.1 | 102.2 | (92.6-112.5) |
| Male | 11 | 7.7 | 142.3 | (71.0-254.7) | Female | 440 | 378.3 | 116.3 | (105.7-127.7) |
| Female | 2 | 2.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 65 | 54.5 | 119.2 | (92.0-152.0) | | | | | |
| Female | 68 | 52.1 | 130.5 | (101.3-165.4) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 3 | 5.0 | nc | (nc-nc) | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 0 | 2.2 | nc | (nc-nc) | Female | 9 | 2.6 | 342.0 | (156.1-649.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 4 | 2.6 | nc | (nc-nc) |
| Female | 29 | 19.3 | 150.5 | (100.8-216.1) | Female | 0 | 2.8 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 3 | 0.7 | nc | (nc-nc) | Male | 3 | 1.8 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 7 | 6.5 | 107.1 | (42.9-220.6) | Female | 3 | 2.0 | nc | (nc-nc) |
| Female | 9 | 7.7 | 116.5 | (53.2-221.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 1.2 | nc | (nc-nc) | Male | 24 | 17.4 | 138.1 | (88.4-205.5) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 2.3 | nc | (nc-nc) | Female | 3 | 4.3 | nc | (nc-nc) |
| Female | 0 | 1.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 76 | 63.4 | 119.9 | (94.4-150.1) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 86 | 70.4 | 122.1 | (97.7-150.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 1.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 1.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 1 | 1.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 2 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 14 | 8.9 | 157.0 | (85.7-263.4) | <u>All Sites / Types</u> | | | | |
| Female | 13 | 10.4 | 125.0 | (66.5-213.8) | <u>All Sites / Types</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.0 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 0.2 | nc | (nc-nc) |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 1 | 2.8 | nc | (nc-nc) |
| Male | 0 | 0.0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.0 | nc | (nc-nc) |
| Male | 0 | 0.3 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 2 | 8.8 | nc | (nc-nc) |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 5.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 1 | 1.2 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 7 | 8.2 | 85.1 | (34.1-175.4) | Male | 9 | 5.0 | 180.2 | (82.2-342.1) |
| Female | 3 | 2.7 | nc | (nc-nc) | Female | 3 | 3.6 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 1.5 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 3 | 1.1 | nc | (nc-nc) | Female | 1 | 0.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 4.3 | nc | (nc-nc) |
| Female | 35 | 26.7 | 131.1 | (91.3-182.3) | Female | 1 | 3.4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.0 | nc | (nc-nc) | Male | 4 | 3.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 5 | 10.9 | 45.9 | (14.8-107.1) | Female | 2 | 2.7 | nc | (nc-nc) |
| Female | 16 | 9.3 | 172.8 | (98.7-280.6) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 3 | 2.5 | nc | (nc-nc) |
| Male | 1 | 2.1 | nc | (nc-nc) | Female | 2 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 37 | 30.6 | 120.8 | (85.1-166.6) |
| Male | 1 | 0.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.4 | nc | (nc-nc) | Male | 2 | 1.9 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 1.0 | nc | (nc-nc) |
| Male | 2 | 4.0 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 2 | 2.2 | nc | (nc-nc) | Male | 2 | 0.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 1.3 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | Female | 3 | 3.9 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 2.7 | nc | (nc-nc) | Female | 6 | 5.9 | 101.2 | (37.0-220.3) |
| Female | 2 | 1.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 95 | 107.4 | 88.4 | (71.5-108.1) |
| Male | 3 | 2.0 | nc | (nc-nc) | Female | 93 | 92.1 | 101.0 | (81.5-123.7) |
| Female | 0 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 8 | 15.0 | 53.3 | (22.9-104.9) | | | | | |
| Female | 7 | 13.1 | 53.3 | (21.4-109.9) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 12 | 6.2 | 193.5 | (99.9-338.1) | Male | 5 | 4.9 | 101.1 | (32.6-235.9) |
| Female | 3 | 2.3 | nc | (nc-nc) | Female | 2 | 4.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.7 | nc | (nc-nc) | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) | Female | 1 | 0.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 5 | 4.1 | 121.2 | (39.1-282.8) |
| Female | 30 | 28.8 | 104.2 | (70.3-148.7) | Female | 4 | 3.2 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.4 | nc | (nc-nc) | Male | 3 | 3.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 10 | 9.2 | 108.3 | (51.9-199.2) | Female | 1 | 2.7 | nc | (nc-nc) |
| Female | 11 | 8.1 | 135.5 | (67.6-242.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 3 | 2.0 | nc | (nc-nc) |
| Male | 2 | 1.9 | nc | (nc-nc) | Female | 3 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 21 | 26.4 | 79.5 | (49.2-121.6) |
| Male | 0 | 0.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.6 | nc | (nc-nc) | Male | 1 | 1.5 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.9 | nc | (nc-nc) |
| Male | 3 | 3.8 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 2.1 | nc | (nc-nc) | Male | 2 | 1.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 5 | 5.4 | 92.9 | (29.9-216.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 2.6 | nc | (nc-nc) | Female | 5 | 6.1 | 81.9 | (26.4-191.2) |
| Female | 0 | 1.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 98 | 94.8 | 103.4 | (83.9-126.0) |
| Male | 2 | 2.0 | nc | (nc-nc) | Female | 90 | 92.6 | 97.2 | (78.2-119.5) |
| Female | 0 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 12 | 11.8 | 101.7 | (52.5-177.6) | | | | | |
| Female | 14 | 11.4 | 122.3 | (66.8-205.2) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 5 | 3.3 | 150.5 | (48.5-351.1) | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) | Female | 3 | 1.5 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 1 | 0.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 12 | 11.0 | 109.1 | (56.3-190.6) | Female | 0 | 1.4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.4 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 6 | 4.3 | 137.9 | (50.4-300.2) | Female | 0 | 1.1 | nc | (nc-nc) |
| Female | 4 | 3.7 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Male | 16 | 11.9 | 134.9 | (77.1-219.1) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 3 | 1.5 | nc | (nc-nc) | Female | 0 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 0.5 | nc | (nc-nc) | Male | 57 | 42.2 | 135.1 | (102.3-175.1) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 30 | 37.6 | 79.7 | (53.8-113.8) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 1 | 0.7 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 6.0 | 117.2 | (46.9-241.4) | <u>All Sites / Types</u> | | | | |
| Female | 3 | 5.4 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 9 | 7.6 | 119.0 | (54.3-225.9) | Male | 4 | 5.9 | nc | (nc-nc) |
| Female | 5 | 2.7 | 187.3 | (60.4-437.2) | Female | 7 | 5.0 | 138.7 | (55.6-285.9) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 2.1 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 3 | 1.6 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 5 | 4.9 | 101.4 | (32.7-236.6) |
| Female | 54 | 33.8 | 159.9 | (120.1-208.7) | Female | 4 | 3.8 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.7 | nc | (nc-nc) | Male | 5 | 3.7 | 136.4 | (43.9-318.2) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 20 | 11.0 | 181.6 | (110.9-280.5) | Female | 2 | 3.2 | nc | (nc-nc) |
| Female | 6 | 9.5 | 63.3 | (23.1-137.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 2.4 | nc | (nc-nc) |
| Male | 3 | 2.2 | nc | (nc-nc) | Female | 9 | 2.3 | 395.5 | (180.5-750.9) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 28 | 30.8 | 91.0 | (60.4-131.5) |
| Male | 0 | 1.0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 0.8 | nc | (nc-nc) | Male | 0 | 1.9 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 3 | 1.0 | nc | (nc-nc) |
| Male | 2 | 4.5 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 2.5 | nc | (nc-nc) | Male | 1 | 1.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 7 | 6.6 | 106.0 | (42.5-218.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 3.1 | nc | (nc-nc) | Female | 7 | 7.2 | 97.1 | (38.9-200.1) |
| Female | 3 | 2.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 119 | 112.7 | 105.6 | (87.5-126.4) |
| Male | 4 | 2.3 | nc | (nc-nc) | Female | 140 | 109.4 | 127.9 | (107.6-151.0) |
| Female | 0 | 0.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 21 | 14.2 | 147.6 | (91.3-225.6) | | | | | |
| Female | 17 | 13.5 | 126.0 | (73.3-201.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|--|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 0.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Female | 4 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | Male | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Female | 1 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Testis</u> | | | | |
| <u>Larynx</u> | | | | | Male | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Female | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 9 | 7.8 | 115.5 | (52.7-219.3) |
| Female | 0 | 0.0 | nc | (nc-nc) | Female | 3 | 6.0 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 1 | 1.0 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.8 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 8 | 5.0 | 159.1 | (68.5-313.5) | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 3 | 1.9 | nc | (nc-nc) | Female | 2 | 3.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.2 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) | Female | 1 | 0.6 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 21 | 21.6 | 97.4 | (60.3-148.9) | Female | 0 | 2.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 1.0 | nc | (nc-nc) | Male | 3 | 2.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 7.2 | nc | (nc-nc) | Female | 3 | 2.1 | nc | (nc-nc) |
| Female | 9 | 7.0 | 129.3 | (59.0-245.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 1.4 | nc | (nc-nc) | Male | 31 | 20.4 | 152.2 | (103.4-216.1) |
| Female | 1 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney & Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 2.9 | 174.2 | (56.1-406.5) | Female | 5 | 4.6 | 108.8 | (35.1-254.0) |
| Female | 1 | 1.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | Male | 84 | 72.9 | 115.2 | (91.9-142.6) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 83 | 72.8 | 114.0 | (90.8-141.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 4 | 1.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 4 | 1.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 2 | 1.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 8 | 9.4 | 85.5 | (36.8-168.4) | <u>All Sites / Types</u> | | | | |
| Female | 4 | 9.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 17 | 9.6 | 176.9 | (103.0-283.2) | Male | 5 | 6.9 | 72.7 | (23.4-169.8) |
| Female | 8 | 3.8 | 208.4 | (89.7-410.7) | Female | 4 | 6.0 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 2.3 | nc | (nc-nc) | Male | 3 | 1.6 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) | Female | 1 | 1.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 8 | 5.8 | 137.6 | (59.3-271.2) |
| Female | 39 | 40.8 | 95.5 | (67.9-130.6) | Female | 8 | 5.2 | 155.3 | (66.9-306.0) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 1 | 1.9 | nc | (nc-nc) | Male | 3 | 4.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 18 | 13.4 | 134.6 | (79.7-212.7) | Female | 6 | 4.0 | 148.2 | (54.1-322.7) |
| Female | 15 | 13.5 | 111.3 | (62.2-183.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 3.0 | nc | (nc-nc) |
| Male | 2 | 2.7 | nc | (nc-nc) | Female | 2 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 49 | 37.8 | 129.7 | (96.0-171.5) |
| Male | 4 | 1.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.9 | nc | (nc-nc) | Male | 2 | 2.3 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 1 | 1.5 | nc | (nc-nc) |
| Male | 4 | 5.3 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 6 | 3.2 | 186.0 | (67.9-404.9) | Male | 5 | 2.0 | 252.5 | (81.4-589.2) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 1.6 | nc | (nc-nc) | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 11 | 7.3 | 150.5 | (75.0-269.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 4 | 3.7 | nc | (nc-nc) | Female | 8 | 8.8 | 91.0 | (39.2-179.3) |
| Female | 4 | 3.0 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 161 | 136.4 | 118.0 | (100.5-137.7) |
| Male | 0 | 2.6 | nc | (nc-nc) | Female | 156 | 140.1 | 111.3 | (94.6-130.3) |
| Female | 1 | 0.9 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 23 | 17.9 | 128.2 | (81.3-192.4) | | | | | |
| Female | 27 | 18.7 | 144.7 | (95.3-210.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 27 | 29.1 | 92.9 | (61.2-135.2) | Male | 17 | 18.0 | 94.3 | (54.9-151.0) |
| Female | 11 | 11.6 | 94.9 | (47.3-169.9) | Female | 15 | 15.0 | 100.2 | (56.1-165.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 8 | 5.5 | 145.3 | (62.6-286.4) | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 2 | 4.7 | nc | (nc-nc) | Female | 7 | 3.7 | 191.0 | (76.5-393.5) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 14 | 15.5 | 90.2 | (49.3-151.4) |
| Female | 125 | 106.7 | 117.1 | (97.5-139.5) | Female | 15 | 14.7 | 101.8 | (56.9-167.9) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 3 | 4.3 | nc | (nc-nc) | Male | 7 | 10.7 | 65.2 | (26.1-134.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 33 | 38.4 | 86.0 | (59.2-120.8) | Female | 13 | 10.9 | 119.1 | (63.3-203.6) |
| Female | 30 | 40.8 | 73.5 | (49.5-104.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 3 | 8.8 | nc | (nc-nc) |
| Male | 5 | 7.4 | 67.3 | (21.7-157.0) | Female | 5 | 10.1 | 49.4 | (15.9-115.4) |
| Female | 2 | 2.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 113 | 104.8 | 107.9 | (88.9-129.7) |
| Male | 1 | 2.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 1.8 | nc | (nc-nc) | Male | 5 | 6.7 | 74.1 | (23.9-172.9) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 7 | 4.6 | 153.0 | (61.3-315.2) |
| Male | 13 | 14.0 | 92.8 | (49.4-158.7) | <u>Testis</u> | | | | |
| Female | 7 | 8.9 | 78.5 | (31.5-161.8) | Male | 2 | 3.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 6 | 4.4 | 136.3 | (49.8-296.8) | Male | 9 | 4.9 | 182.0 | (83.0-345.4) |
| Female | 1 | 1.3 | nc | (nc-nc) | Female | 14 | 15.9 | 87.8 | (48.0-147.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 9 | 9.8 | 92.0 | (42.0-174.6) | Female | 19 | 23.3 | 81.4 | (49.0-127.1) |
| Female | 9 | 8.1 | 111.7 | (51.0-212.0) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 356 | 378.2 | 94.1 | (84.6-104.4) |
| Male | 8 | 6.9 | 115.2 | (49.6-227.1) | Female | 378 | 383.3 | 98.6 | (88.9-109.1) |
| Female | 2 | 2.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 39 | 52.7 | 74.1 | (52.7-101.2) | | | | | |
| Female | 51 | 54.7 | 93.2 | (69.4-122.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|---|------------|------------|------------|---------------|--|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 1.4 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 2 | 0.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 2 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 9 | 6.5 | 138.9 | (63.4-263.8) | Female | 0 | 0.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity & Pharynx</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 2 | 0.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 2.1 | nc | (nc-nc) | Female | 3 | 0.6 | nc | (nc-nc) |
| Female | 3 | 1.7 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 0.5 | nc | (nc-nc) |
| Male | 1 | 0.4 | nc | (nc-nc) | Female | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 5 | 6.6 | 75.9 | (24.4-177.1) |
| Male | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| <u>Kidney & Renal Pelvis</u> | | | | | Female | 0 | 0.2 | nc | (nc-nc) |
| Male | 1 | 0.9 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 1.2 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Female | 0 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 24 | 22.1 | 108.7 | (69.6-161.8) |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 24 | 20.4 | 117.7 | (75.4-175.2) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 4 | 2.8 | nc | (nc-nc) | | | | | |
| Female | 4 | 2.5 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;